Fibroblast growth factor-1

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Fibroblast growth factor-1
Accession Number
DB05599
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Acidic fibroblast growth factor
  • Acidic fibroblast growth factor (aFGF)
  • Fibroblast growth factor, acidic
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Le-Blen FGF SerumFibroblast growth factor-1 (0.54 g/56.7g) + Glycerin (14.18 g/56.7g) + Sodium hyaluronate (0.4 g/56.7g)EmulsionTopicalLeBlen Beauty Inc.2018-04-24Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Le-Blen FGF SerumFibroblast growth factor-1 (0.54 g/56.7g) + Glycerin (14.18 g/56.7g) + Sodium hyaluronate (0.4 g/56.7g)EmulsionTopicalLeBlen Beauty Inc.2018-04-24Not applicableUs
International/Other Brands
Cardio Vascu-Grow
Categories
UNII
G53298VN9Y
CAS number
106096-92-8

Pharmacology

Indication

Investigated for use/treatment in coronary artery disease and peripheral vascular disease.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentCoronary Arteriosclerosis / Coronary Heart Disease (CHD) / Myocardial Ischemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
EmulsionTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:26 / Updated on September 02, 2019 18:14